Perimenopause HRT: transdermal estradiol + micronized progesterone, explained

What HRT actually is

HRT replaces the hormones your ovaries are winding down. Two main hormones, one optional add-on:

• Estrogen (usually estradiol). The heavy lifter. Treats hot flashes, night sweats, brain fog, mood, sleep, joint pain, vaginal dryness, and protects bone.
• Progesterone (usually micronized progesterone). Required if you still have a uterus, to protect the uterine lining from estrogen's proliferative effect. Also modestly sedating — taken at night, it often helps sleep.
• Testosterone (optional, off-label in most countries). Sometimes added for low libido, energy, or muscle preservation. Prescribed by menopause specialists more than general practitioners.

Delivery methods, ranked

Route matters more than most people realize. Transdermal estradiol avoids the liver, which is where oral estrogen raises clotting factors.

• Patch. Twice-weekly stick-on. Steady levels. First choice for most women. No clot-risk signal.
• Gel or spray. Daily application to the skin. Equivalent safety to patches. Good for people whose skin doesn't tolerate patches.
• Oral pill. Equally effective for symptoms, but carries a small extra clot risk because of first-pass liver metabolism. Reasonable when transdermal isn't tolerated or available.
• Vaginal estrogen (cream, ring, tablet). A completely separate, very-low-dose local treatment for genitourinary symptoms (dryness, painful sex, recurrent UTIs). Not systemic. Safe for many women who can't take systemic HRT.

Who HRT is for

• Women with moderate to severe vasomotor symptoms (hot flashes, night sweats).
• Women with early or premature menopause (under 45) — treatment is more important, not less.
• Women with genitourinary symptoms (local vaginal estrogen has an even wider indication).
• Women at elevated risk of osteoporosis where non-hormonal options aren't suitable.
• Women whose sleep, mood, or quality of life is meaningfully affected — this is a valid reason on its own.

Who should be cautious or avoid systemic HRT

• Active or recent breast cancer.
• Active clotting disorder or recent VTE (transdermal may still be discussed with a specialist).
• Unexplained vaginal bleeding — investigate first.
• Active liver disease.
• Known hormone-sensitive cancer, current or recent.

Note: high blood pressure, migraine with aura, diabetes, and obesity are NOT automatic contraindications, but they do push the conversation toward transdermal and toward a menopause specialist.

The 2002 study and what actually changed

The Women's Health Initiative (WHI) enrolled women with an average age of 63 — well past the ideal treatment window — and used oral conjugated equine estrogens plus medroxyprogesterone acetate, a synthetic progestin. It reported small absolute increases in breast cancer, stroke, and clots. The headlines dropped HRT prescribing by roughly 80% in a few years.

Re-analyses since then have made three things clear: (1) starting HRT in perimenopause or within 10 years of menopause, in women under 60, looks very different from starting it in a 65-year-old — the cardiovascular benefit-risk balance flips positive. (2) Transdermal estradiol does not carry the same clot risk as oral. (3) Micronized progesterone appears safer for breast tissue than the synthetic progestin used in WHI. Modern HRT is not the HRT that was studied in 2002.

How to talk to your doctor

• Bring a symptom log covering 2 to 4 weeks. Frequency, severity, sleep impact.
• Ask specifically about transdermal estradiol plus micronized progesterone.
• If you're refused, ask why in writing. Reasons like "you're too young" or "you're still having periods" are not evidence-based in current guidelines.
• If your primary care doctor is uncomfortable, ask for a referral to a gynecologist or menopause specialist. In the US, the Menopause Society keeps a directory of certified practitioners at menopause.org.
• Telemedicine menopause clinics (Midi, Alloy, Evernow) exist for exactly this gap. They are legitimate options if your local care is unresponsive.

What to actually say at the appointment

Verbatim phrases that get you past the shrug. Pick the ones that fit your situation, screenshot, take them in:

• "I'd like to discuss transdermal estradiol and micronized progesterone based on current Menopause Society guidance."
• "My symptoms are affecting my sleep, work, and quality of life. I understand HRT is first-line for moderate-to-severe vasomotor symptoms."
• "I know I'm still getting periods. Current guidelines don't require me to be postmenopausal to start HRT. Can we talk about a cyclical regimen?"
• "If you're not comfortable prescribing, could you refer me to a menopause specialist or a certified menopause practitioner?"
• "Can you document your reasoning in my chart? I'd like to understand the specific risk factor you're weighing."

The last one, calm, professional, in writing, tends to move the conversation more than any argument you could make out loud.

Typical starting doses (so you know if what you're offered is standard)

This is not a prescription. It's a reality check, so you can tell whether the plan you're offered is inside normal starting ranges or oddly conservative. Ranges vary by country and product.

• Estradiol patch: typical starting dose 0.025 to 0.05 mg per 24 hours, changed once or twice a week depending on brand. Younger perimenopausal women often need the higher end.
• Estradiol gel: 0.5 to 1.0 mg per day (roughly one to two pumps of most branded gels), applied to arms or thighs.
• Estradiol spray: one to three sprays daily, product-specific.
• Micronized progesterone (oral): 100 mg nightly (continuous, if periods have stopped or spaced far apart) or 200 mg nightly for 12 days a month (cyclical, if you're still cycling). Taken at night, it's mildly sedating.
• Vaginal estradiol: a low-dose local treatment, tablets, ring, or cream. Separate from systemic HRT and often used alongside it, or on its own for genitourinary symptoms.
• Testosterone (off-label in the US): small daily doses of a compounded or transdermal product, prescribed mostly by menopause specialists.

If you're offered a starting dose well below these ranges without a specific reason (a personal risk factor, a trial of the lowest possible dose you both agreed to), it's fair to ask why.

What to expect in the first three months

• Weeks 1 to 2. Some breast tenderness, mild bloating, or spotting is common as your body adjusts. Usually fades.
• Weeks 2 to 4. Hot flashes and night sweats usually start easing. Sleep often improves noticeably.
• Months 2 to 3. Mood, brain fog, joint pain, and energy typically shift. Vaginal symptoms take longer, especially with systemic-only treatment — many women add local vaginal estrogen too.
• Month 3 review. If symptoms aren't meaningfully better, the dose or route can be adjusted. Don't stop at week 4.

Non-hormonal alternatives

If HRT isn't right for you, options exist. For hot flashes: fezolinetant (a newer NK3 antagonist), low-dose SSRIs/SNRIs (paroxetine, venlafaxine, escitalopram), gabapentin, or clonidine. For sleep: CBT-I. For mood: SSRIs, CBT. For bone: bisphosphonates or newer bone-building drugs. For genitourinary symptoms: low-dose vaginal estrogen (very different risk profile from systemic).

Where to read the actual guidelines

If you want the source material rather than the summaries:

• The Menopause Society (US) — hormone therapy position statements and practitioner directory.
• British Menopause Society — consensus statements and prescribing guidance.
• International Menopause Society — white papers and global recommendations.